Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Eric L. Haseltine
Observed names:
E. Haseltine,
E. L. Haseltine,
Eric Haseltine,
Haseltine, Eric
Institution:
Vertex Pharmaceuticals (United States)
Observed institutions:
California Institute of Technology,
University of Wisconsin–Madison,
Vertex Pharmaceuticals (United States)
ORCID:
0000-0002-3172-6299
Observed ORCID:
0000-0002-3172-6299
OpenAlex ID:
A5064938391
Approximate simulation of coupled fast and slow reactions for stochastic chemical kinetics
2002
·
Eric L. Haseltine
, James B. Rawlings
·
The Journal of Chemical Physics
·
565
PDF
Critical Evaluation of Extended Kalman Filtering and Moving-Horizon Estimation
2004
·
Eric L. Haseltine
, James B. Rawlings
·
Industrial & Engineering Chemistry Research
·
500
Synthetic Gene Circuits: Design with Directed Evolution
2007
·
Eric L. Haseltine
, Frances H. Arnold
·
Annual Review of Biophysics and Biomolecular Structure
·
129
Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial
2020
·
Jane C. Davies
, Claire E. Wainwright
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
103
Two classes of quasi-steady-state model reductions for stochastic kinetics
2007
·
Ethan A. Mastny
, Eric L. Haseltine
, et al.
·
The Journal of Chemical Physics
·
97
Implications of Rewiring Bacterial Quorum Sensing
2007
·
Eric L. Haseltine
, Frances H. Arnold
·
Applied and Environmental Microbiology
·
80
On the origins of approximations for stochastic chemical kinetics
2005
·
Eric L. Haseltine
, James B. Rawlings
·
The Journal of Chemical Physics
·
72
A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation
2020
·
Jane C. Davies
, Isabelle Sermet-Gaudelus
, et al.
·
Journal of Cystic Fibrosis
·
70
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis
2019
·
Seth Walker
, Patrick Flume
, et al.
·
Journal of Cystic Fibrosis
·
60
PDF
Initialization strategies for optimization of dynamic systems
2015
·
Seyed Mostafa Safdarnejad
, John D. Hedengren
, et al.
·
Computers & Chemical Engineering
·
54
Dynamics of viral infections: incorporating both the intracellular and extracellular levels
2004
·
Eric L. Haseltine
, James B. Rawlings
, et al.
·
Computers & Chemical Engineering
·
40
Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor
2020
·
Alice Tsai
, Shu-Pei Wu
, et al.
·
Pulmonary Therapy
·
38
PDF
Image-Guided Modeling of Virus Growth and Spread
2008
·
Eric L. Haseltine
, Vy Lam
, et al.
·
Bulletin of Mathematical Biology
·
37
On the stochastic simulation of particulate systems
2005
·
Eric L. Haseltine
, Daniel B. Patience
, et al.
·
Chemical Engineering Science
·
30
The stochastic quasi-steady-state assumption: Reducing the model but not the noise
2011
·
Rishi Srivastava
, Eric L. Haseltine
, et al.
·
The Journal of Chemical Physics
·
23
PDF
Stochastic simulation of catalytic surface reactions in the fast diffusion limit
2006
·
Ethan A. Mastny
, Eric L. Haseltine
, et al.
·
The Journal of Chemical Physics
·
20
Successful treatment with telaprevir‐based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis
2015
·
E. L. Haseltine
, M. S. Penney
, et al.
·
Journal of Viral Hepatitis
·
15
Hybrid Dynamic Optimization Methods for Systems Biology with Efficient Sensitivities
2015
·
Nicholas Lewis
, John Hedengren
, et al.
·
Processes
·
12
PDF
Implications of decoupling the intracellular and extracellular levels in multi‐level models of virus growth
2008
·
Eric L. Haseltine
, John Yin
, et al.
·
Biotechnology and Bioengineering
·
12
A signature for immune response correlates with HCV treatment outcome in Caucasian subjects
2015
·
Brian J. Hare
, Eric Haseltine
, et al.
·
Journal of Proteomics
·
7
Modeling Viral Evolutionary Dynamics after Telaprevir-Based Treatment
2014
·
Eric L. Haseltine
, Sandra De Meyer
, et al.
·
PLoS Computational Biology
·
7
A signature for immune response correlates with HCV treatment outcome in Caucasian subjects
2015
·
Brian J. Hare
, Eric Haseltine
, et al.
·
Data in Brief
·
6
Correction to: Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor
2020
·
Alice Tsai
, Shu-Pei Wu
, et al.
·
Pulmonary Therapy
·
2
PDF
THU0242 Vx-509 (DECERNOTINIB) Treatment Reduces Levels of Markers for Immune Activation, Bone Degradation and Inflammation but not Interferon Signaling in Patients with Rheumatoid Arthritis
2014
·
B.J. Hare
, E. Haseltine
, et al.
·
Annals of the Rheumatic Diseases
·
1
Optimizing Pediatric Doses for Weight-Based Dosing Regimens Under Constraints
2026
·
Eric Haseltine
, Emily McDougall
, et al.
Show more works
View as search
Works count:
34
Citation count:
1,981
H-index:
16
I10-index:
19
Year
Topic
Type
